What 4 Analyst Ratings Have To Say About Black Diamond Therapeutic
Portfolio Pulse from Benzinga Insights
In the last quarter, 4 analysts have provided ratings for Black Diamond Therapeutic (NASDAQ:BDTX), with 1 being bullish, 1 somewhat bullish, and 2 indifferent. The company has an average 12-month price target of $6.5, up 116.67% from the previous average of $3.00.
June 28, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Black Diamond Therapeutic has received mixed ratings from analysts, with an average 12-month price target of $6.5, indicating potential upside.
The average 12-month price target for BDTX has increased significantly, suggesting that analysts see potential upside for the stock. However, the mixed ratings indicate some uncertainty, which could lead to volatility in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100